High-speed reliable detection of cancer cells in blood

高速可靠地检测血液中的癌细胞

• 批准号: 7284861
• 负责人: Richard H. Bruce
• 金额: $ 91.11万
• 依托单位: PALO ALTO RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-06 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7284861
• 关键词: Antigens; Area; Automation; Biomedical Engineering; Blood; Blood Cells; Blood specimen; Cancer Center; Cancer Patient; Cancer Research Project; Cell Count; Cell Line; Cells; Clinic; Clinical; Clinical Oncology; Collaborations; Computer software; Data; Detection; Development; Diagnostic Neoplasm Staging; Disclosure; Disease; Disseminated Malignant Neoplasm; Doctor of Philosophy; Engineering; Enrollment; Fiber; Heterogeneity; Human; Image; Incidence; Institution; Label; Lead; Malignant Neoplasms; Measures; Mechanics; Medical; Medicine; Methods; Microscopy; Monitor; Numbers; Optics; Pathology; Patients; Performance; Population; Preparation; Prevalence; Principal Investigator; Procedures; Process; Protocols documentation; Publishing; Rate; Recurrent disease; Relapse; Reporting; Research; Research Institute; Research Personnel; Research Subjects; Resolution; Risk; Sampling; Scanning; Screening for cancer; Specificity; Specimen Handling; Speed; Stage at Diagnosis; Staging; Statistically Significant; System; Technology; Time; Title; Today; United States Food and Drug Administration; Validation; Visual; base; burden of illness; cancer cell; cell preparation; cohort; computerized data processing; concept; cost; design; experimental analysis; improved; instrument; interdisciplinary approach; malignant breast neoplasm; method development; multidisciplinary; neoplastic cell; new technology; oncology; peripheral blood; programs; prototype; response

DESCRIPTION (provided by applicant): The medical value of detecting circulating tumor cells (CTCs) in peripheral blood is now established, and a specific approach has FDA approval for managing metastatic patients. While the value is clear, it is also limited in application. For example, the reported results are uninformative for a large percentage of metastatic patients, and no validation exists for earlier stages. The cancer bioengineering research partnership (CBRP) proposes to develop a technology for CTC detection that overcomes these limitations. We will develop a new instrument, the Fiber Array Scan Technology (FAST) cytometer that efficiently scans the large numbers of cells required to detect CTCs and a cell preparation protocol that is optimized for cell retention. We will use these developments to investigate whether more metastatic patients have CTCs than current approaches indicate. We will also investigate the medical efficacy of CTC detection in early stage cancer patients. In addition we will investigate applications for staging at diagnosis, as well as for longitudinal therapy monitoring and long-term patient management. The effort integrates clinical oncology with biophysical analysis methods and opto-mechanical engineering. The CBRP will develop a rare cell detection system that can analyze approximately 50 million cells in 2 minutes with a sensitivity of 10% false negatives and a false positive ratio of less than 1 in 107. The Lead Investigators of the CBRP have developed the initial proof of concept through a multidisciplinary approach bridging optical design, statistical software analysis, experimental medicine, oncology, and pathology at the leading institutions, the Palo Alto Research Center (PARC) and The Scripps Research Institute (TSRI), as well as at the participating institutions, Scripps Clinic and the Scripps Cancer Center. The lead investigators are Richard Bruce, Ph.D. (PARC), who is the principal investigator and will in addition lead the optical and system engineering efforts; Peter Kuhn, Ph.D. (TSRI), who will lead the experimental processing; and Jorge Nieva, MD (TSRI and Scripps Cancer Center), who will lead the oncology and pathology of the CBRP. The lead investigators are experts in their respective fields and provide the required expertise for the multi-disciplinary research program of the CBRP.

描述（由申请人提供）：现在已经建立了外周血中检测循环肿瘤细胞（CTC）的医学价值，并且一种特定的方法已获得用于管理转移性患者的FDA批准。虽然值很明显，但应用程序也受到限制。例如，报告的结果对于大量转移性患者而言是无信息的，并且不存在较早阶段的验证。癌症生物工程研究合作伙伴关系（CBRP）提议开发一种克服这些限制的CTC检测技术。我们将开发一种新的仪器，即纤维阵列扫描技术（快速）细胞图仪，该仪表仪有效扫描检测CTC所需的大量细胞，以及针对细胞保留的优化的细胞制备方案。我们将使用这些发展来调查更多的转移性患者是否具有比当前方法指出的CTC。我们还将研究早期癌症患者CTC检测的医疗功效。此外，我们将调查用于诊断时分期的应用，以及纵向治疗监测和长期患者管理。这项工作将临床肿瘤学与生物物理分析方法和光学机械工程相结合。 The CBRP will develop a rare cell detection system that can analyze approximately 50 million cells in 2 minutes with a sensitivity of 10% false negatives and a false positive ratio of less than 1 in 107. The Lead Investigators of the CBRP have developed the initial proof of concept through a multidisciplinary approach bridging optical design, statistical software analysis, experimental medicine, oncology, and pathology at the leading institutions, the Palo Alto Research Center (PARC) and The Scripps研究所（TSRI）以及参与机构Scripps诊所和Scripps癌症中心。首席研究人员是理查德·布鲁斯（Richard Bruce）博士。 （PARC），他是主要研究人员，此外将领导光学和系统工程工作；彼得·库恩（Peter Kuhn）博士（TSRI），他将领导实验处理；医学博士Jorge Nieva（TSRI和Scripps癌症中心），他们将领导CBRP的肿瘤学和病理学。首席研究人员是各自领域的专家，并为CBRP的多学科研究计划提供了所需的专业知识。